The Andrea Schietinger Lab
The goal of our laboratory is to understand when, why, and how immune cells become unresponsive to tumors or self-destructive in autoimmune diseases. We develop genetic cancer mouse models that mimic cancer development in patients, investigate T cell responses over the course of tumor development, and define the molecular mechanisms that are responsible for the failure to control and eliminate tumors. In addition, we utilize clinically relevant mouse models of autoimmunity, such as Type 1 Diabetes, to understand how autoimmune responses are initiated and sustained. Our ongoing and future research programs aim to develop a deep mechanistic understanding of the spatiotemporal, molecular, and epigenetic factors that determine T cell fate decisions and functional/dysfunctional states in cancer and autoimmunity, and test innovative conceptual frameworks and T cell reprogramming approaches for the treatment of T cell-mediated diseases. Detailed information about our research is available at www.schietingerlab.com.
Gearty SV, Dündar F, Zumbo P, Espinosa-Carrasco G, ShakibaM, Sanchez-RiveraF, SocciND, Trivedi D, LoweSW, LauerP, Mohibullah N, DiLorenzo TP, Viale A, Betel D, Schietinger A. A stem-like autoimmune CD8 T cell population drives type 1 diabetes. Nature 2022 Feb;602(7895):156-161.
Shakiba M, Zumbo P, Dündar F, Espinosa-Carrasco G, Camara S, Sanchez-Rivera FG, Lowe SW, Koche RP, Reuter VP, Socci ND, Whitlock B, Tamzalit F, Huse M, Betel D, Philip M, Schietinger A. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. Journal of Experimental Medicine 2022 Feb 7;219(2):e20201966.
Philip M and Schietinger A. CD8 T cell differentiation and dysfunction in cancer. Nature Reviews Immunology. 2022 Apr;22(4):209-223.
TOX is a critical regulator of tumour-specific T cell differentiation. Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.
Andrea Schietinger, PhD
Associate Member, Immunology Program, SKI
- Cancer Immunologist Andrea Schietinger investigates immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy.
- PharmD, University of Hamburg, PhD, University of Chicago, Chicago, IL and University of Munich, Germany
- Postdoctoral Training: Fred Hutchinson Cancer Research Center and University of Washington, Seattle
- [email protected]
- Email Address
- Office Phone
- Office Phone
- BS, The City College of New York
- AACR-Irving Weinstein Foundation Distinguished Lectureship Award (2023)
- American Association of Immunologists - AAI BD Biosciences Investigator Award (2022)
- AACR-Bristol Myers Squibb Midcareer Female Investigator Award (2021)
- Catherine and Frederick R. Adler Chair for Junior Faculty (2021)
- Louise and Allston Boyer Young Investigator Award for Basic Research (2020)
- Pershing Square Sohn Award (2020)
- Josie Robertson Investigator (2014-2019)
- Cancer Research Institute Lloyd Old STAR Award (2019)
- NIH Director’s Innovator Award (2017)
- NIH/NCI K99/R00 Award (2015)
- V Foundation for Cancer Research Award (2015)
- William and Ella Owens Medical Research Foundation Award (2016)
- Cancer Research Institute Irvington Fellowship (2012)
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Lab Head Email
Assistant: Nadine Hernandez
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrea Schietinger discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].